Get the Daily Brief
Latest Biotech News
Oral GLP‑1 pill posts strong Phase 2 weight loss – 16% at 44 weeks
Structure Therapeutics reported Phase 2 data showing its oral GLP‑1 candidate aleniglipron produced up to a 16% placebo‑adjusted weight reduction at 44 weeks, positioning the drug as a...
Roche and Nvidia strike deal: building pharma’s largest AI 'factory'
Roche signed a strategic partnership with Nvidia to build an expansive AI computing ecosystem aimed at accelerating drug discovery, diagnostics development, and internal R&D workflows. The plan...
Manufacturing push: ARPA‑H funds digital gene‑therapy platform; AutoCell automation advances
Public and private actors are investing in manufacturing solutions to unlock scalable gene and cell therapy production. ARPA‑H awarded BioCurie up to $9.3 million to build an AI‑driven,...
Astellas ends CytomX pact as CytomX posts encouraging CRC ADC data
Astellas walked away from its multi‑year collaboration with CytomX, exiting a partnership that originally carried up to $1.6–$1.7 billion in potential milestones. The split follows shifting...
PerturbAI publishes 8M‑cell in vivo CRISPR atlas and exits stealth
PerturbAI emerged from stealth while releasing a publicly accessible in vivo CRISPR perturbation atlas mapping gene function across 8 million brain cells. The dataset, generated using the...
Lipid innovations sharpen tissue targeting and immune tuning for LNPs
Two independent advances in lipid nanoparticle design promise to improve mRNA and gene‑therapy delivery by tuning tissue tropism and immune cell metabolism. Researchers described a class of...
In vivo base editing reverses neurodevelopmental disorder in preclinical model
Researchers reported that in vivo base editing corrected a pathogenic mutation and reversed disease phenotypes in a preclinical model of a neurodevelopmental disorder. The study demonstrates...
R1 Therapeutics raises $77.5M to advance AP‑306 for hyperphosphatemia in CKD
R1 Therapeutics launched with a $77.5 million Series A to develop AP‑306, an oral pan‑phosphate transporter inhibitor targeting hyperphosphatemia in chronic kidney disease and dialysis patients....
Oral GLP-1 pill rivals injectables: Structure posts 44‑week, phase‑2 win
Structure Therapeutics reported Phase 2 results showing its oral GLP‑1 candidate aleniglipron produced substantial, sustained weight loss in a 44‑week study. The company said participants on...
Federal judge freezes ACIP overhaul: vaccine schedule, appointments stayed
A federal judge issued a stay pausing major elements of Health and Human Services Secretary Robert F. Kennedy Jr.'s overhaul of the Advisory Committee on Immunization Practices (ACIP) and the...
CytomX data and Astellas exit: masked ADC story tightens
CytomX reported encouraging Phase 1 expansion data for its masked, conditionally activated antibody‑drug conjugate Varseta‑M in late‑line metastatic colorectal cancer, showing response rates up to...
Standardizing genomic pipeline: metapipeline‑DNA goes cloud‑scale
Researchers from Sanford Burnham Prebys and UCLA released metapipeline‑DNA, an automated, extensible Nextflow pipeline for germline and somatic DNA sequencing analysis designed for cloud and HPC...
ARPA‑H funds digital gene‑therapy manufacturing: $9.3M award to BioCurie
ARPA‑H awarded BioCurie up to $9.3 million to build an AI‑driven, data‑centric platform for scalable gene‑therapy manufacturing. The program seeks to replace trial‑and‑error process development...
LNP chemistry advances: redesigned lipids and media tweaks raise delivery bar
Two separate preclinical efforts reported improvements to lipid nanoparticle (LNP) performance for mRNA and gene therapies. University of Pennsylvania researchers showed crosslinked ionizable...
PerturbAI publishes 8M‑cell in‑vivo CRISPR atlas: public resource for causal genomics
PerturbAI emerged from stealth with a public in‑vivo Perturb‑seq atlas mapping gene function across 8 million mouse brain cells. The San Francisco startup, backed by a pre‑seed round and...
Big pharma builds an AI factory: Roche, Nvidia expand compute for drug R&D
Roche confirmed plans to expand its partnership with Nvidia to build a large AI 'factory' aimed at accelerating drug discovery and diagnostic development, following a broader pharma push to secure...
In vivo base editing reverses neurodevelopmental disorder – preclinical milestone
Researchers published results showing in‑vivo base editing corrected a genetic lesion and reversed disease phenotypes in a neurodevelopmental disorder model. The work, reported in Nature...
New renal biotech R1 raises $77.5M to advance oral hyperphosphatemia drug
R1 Therapeutics launched with an oversubscribed $77.5 million Series A to advance AP‑306, an oral pan‑phosphate transporter inhibitor for hyperphosphatemia in chronic kidney disease (CKD). The...
Judge halts overhaul of U.S. childhood vaccine policy — ACIP appointments stayed
A federal judge has temporarily blocked major elements of Health and Human Services Secretary Robert F. Kennedy Jr.’s changes to U.S. childhood immunization policy, staying votes by the...
R1 Therapeutics launches with $77.5M to advance AP306 for dialysis-related hyperphosphatemia
R1 Therapeutics unveiled a $77.5 million Series A to develop AP306 (formerly EOS789), a pan‑phosphate transporter inhibitor targeting hyperphosphatemia in chronic kidney disease patients on...